Icosavax provided a corporate update and highlighted anticipated milestones for 2023. "We enter 2023 energized by the recent six-month immunogenicity data from our IVX-121 Phase 1/1b study, which we believe provides the first clinical evidence of potential differentiation on durability using Icosavax’s VLP platform technology," said Adam Simpson, Chief Executive Officer of Icosavax. "With the Phase 1 trial of IVX-A12 — our differentiated, bivalent vaccine combination of IVX-121 for RSV and IVX-241 for hMPV — on track to report topline results in mid-2023, and with our plans to initiate a Phase 2 study of IVX-A12 in the second half of the year, I believe we are poised to make further strides towards our vision of creating pan-respiratory vaccines for older adults." Near-Term Milestone Expectations: IVX-121 Phase 1b extension, 12-month immunogenicity data expected in mid-2023; IVX-A12 Phase 1 topline interim data expected in mid-2023; IVX-A12 Phase 2 initiation expected in 2H 2023; Flu program candidate selection expected in 2023; COVID-19 bivalent candidate selection expected in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICVX:
- Icosavax Provides Corporate Update and Anticipated Milestones for 2023
- Oppenheimer starts Icosavax with Outperform on ‘robust” RSV data
- Icosavax initiated with an Outperform at Oppenheimer
- Icosavax reports durability data for VLP vaccine IVX-121 against RSV
- Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
